TherapiAI’s Conversational AI Agent Platform Enables Real-World CDMO Transformation TherapiAI’s proprietary AI agent platform features a conversational interface that allows users in the biotech and pharmaceutical sectors to build complex models such as cell line selection and cell process optimization using natural language commands. The platform integrates multiple biomedical databases to accelerate data access and model deployment, enabling pharmaceutical CDMOs to significantly shorten product delivery timelines. To meet the industry’s strict data security requirements, TherapiAI also supports enterprise-level deployment through on-premise or private cloud environments, minimizing the risk of cloud-based data leakage. The solution has already been adopted by several domestic CDMO partners, who have reported marked improvements in process efficiency and substantial cost reductions. At the recent forum, TherapiAI invited several industry leaders to present practical use cases of AI in pharmaceutical manufacturing. Merck Life Science showcased the use of Raman spectroscopy for real-time process monitoring, significantly improving quality and operational stability. Japan’s leading cell therapy CDMO, Cyto Facto, demonstrated its RFID-based solution for raw material tracking and product authentication, enabling end-to-end digitalization. Taiwan-based Dr.Signal shared its integration of IoT, AI simulation, and digital twin technologies to enable autonomous production and intelligent scheduling in smart manufacturing environments. In another highlight, Dr. Jung-Hao Wang from a global CDMO presented a cutting-edge approach to molecular optimization. Using large language models to screen antibody sequences, his team evaluates molecular stability, immunogenicity, and expression potential. Combined with early-stage immunoreactivity testing, the method helps predict and mitigate immune risks. These real-world applications illustrate that AI is moving beyond proof-of-concept and into critical production workflows, enabling advancements in cell screening, process analytics, quality management, and document automation. With simultaneous expansion across Taiwan and Japan and a growing portfolio of practical deployments, TherapiAI is poised to further strengthen its ecosystem partnerships and lead the implementation of end-to-end AI-powered solutions across the Asian pharmaceutical CDMO landscape.

Language

Clients & Strategic Partners

Government / Hospital

Biomedical Industry

Doctors

Kun-Yi Lin

YUAN-TA Lin

Anna Luan

Jeffrey Yao

Zeshaan N Maan